San Diego, CA (Vocus) February 12, 2009
The American Pain Society (APS) in conjunction with the American Academy of Pain Medicine (AAPM) has released the first comprehensive clinical practice guideline to assist doctors in prescribing opioid pain medications for patients experiencing chronic pain.
The new guidelines set out what the law is likely to recognize as a new standard of care in the pain community, and contain several specific recommendations for initial patient encounters and patient follow up care and risk management. The new clinical guidelines appear in the latest of The Journal of Pain.
Millenium Laboratories' Commitment and Response:
Millenium Laboratories has been monitoring several recent developments in the courts and within DEA, and advising its clients to learn about medical and legal updates on risk management. Millenium has partnered with national medical and legal experts to educate its existing clients on the these new guidelines and recent DEA developments to illustrate the importance of urine drug testing as part of a comprehensive risk management program.
Millenium Laboratories will initially present this training through Audio Town Hall programs, currently scheduled for February 12th at 12:00-1:00 EST 1:00-2:00EST and 2:00-3:00EST. Town Hall space is limited, so clients should sign up by contacting Millenium Laboratories at (877) 451-3534 . Non-clients also welcome and should contact Millenium Laboratories to register.
Millenium will present additional town halls on Monday, February 16th and Friday, February 20th, at 12:00-1:00 EST 1:00-2:00EST and 2:00-3:00EST.
Millenium will also provide live regional training and current clients should speak with their Independent Sales Representatives for time and location.
Millenium continues to partner with national experts and to obtain feedback from its clients relating to risk management needs, and is committed to help clients stay current with the changing medico-legal landscape. The government has characterized the abuse and diversion of prescription controlled medications as a 'public health and safety crisis,' and the new clinical guidelines leave little room for doubt about the important role urine drug testing plays in the risk management equation.
Additional questions about the new guidelines and DEA commentary should be directed to Millenium Laboratories at (877) 451-3534.